NEWS legal form changed ByOncoscience 22. August 201717. July 2025 We are now Oncoscience GmbH. Managing directors are Dr. Dirk Reuter, Dr. Budhi Simon and Robert Ellerson. Ähnliche Beiträge
NEWS Oncoscience AG attends the Nimotuzumab Global Scientific Meeting, 7th-10th April 2016 in Varadero/ Cuba ByOncoscience 7. April 201617. July 2025
NEWS Oncoscience AG presents results from Phase III study of Nimotuzumab (Theraloc®) in patients with diffuse intrinsic pontine glioma at the 41. SIOP, Sao Paulo, Brazil, October 6th-9th, 2009 ByOncoscience 9. October 200917. July 2025
NEWS Oncoscience AG receives EU orphan drug status for the EGFR monoclonal antibody Nimotuzumab (Theraloc®) for the treatment of pancreatic cancer. ByOncoscience 22. April 200817. July 2025
NEWS Oncoscience AG established scientific advisory board ByOncoscience 15. October 200417. July 2025
NEWS Oncoscience AG announces completion of patient enrollment in phase III trial of NIMOTUZUMAB, in first line treatment of children with inoperable brain cancer ByOncoscience 12. September 200717. July 2025
NEWS Oncoscience signs contract with YM Biosciences Inc. ByOncoscience 15. November 200317. July 2025